Oncologist and Patient Preferences for Attributes of CDK4/6 Inhibitor Regimens for the Treatment of Advanced/Metastatic HR Positive/HER2 Negative Breast Cancer: Discrete Choice Experiment and Best–Worst Scaling

PURPOSE: To understand and compare preferences for dosing- and toxicity-related attributes associated with selective cyclin-dependent 4/6 kinase inhibitors regimens among US oncologists and patients. MATERIALS AND METHODS: Oncologists and patients with mBC participated in an internet-based survey th...

Descripción completa

Detalles Bibliográficos
Autores principales: Maculaitis, Martine C, Liu, Xianchen, Will, Oliver, Hanson, Madelyn, McRoy, Lynn, Berk, Alexandra, Crastnopol, Melissa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2020
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7652230/
https://www.ncbi.nlm.nih.gov/pubmed/33177814
http://dx.doi.org/10.2147/PPA.S254934

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7652230/
https://www.ncbi.nlm.nih.gov/pubmed/33177814
http://dx.doi.org/10.2147/PPA.S254934

Ejemplares similares